![]() ![]() Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date of January 26, creates anticipation for NET portfolio expansion Other liabilities (incl.Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Provisions for pensions and similar obligations Result from discontinued operations (net of tax) Recurring pretax income from continuing operations Source: Company data, Hauck & Aufhäuser Close price as of: BUY with an unchanged PT of € 172 based on SOTP. ![]() Radioligand therapy (RLT) pipeline includes 177Lu-PSMA-R2 entering Phase 1/2 study for prostate cancerīasel, JanuNovartis AG ( NVS) today announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of the outstanding ordinary shares ("Ordinary Shares"), including Ordinary Shares represented by American Depositary Shares ("ADSs"), of Advanced Accelerator Applications S.A. ( AAAP) ("AAA"), for a price of USD 41.00 per Ordinary Share and USD 82.00 per ADS, in each case payable net to the seller in cash, without interest (the "Offer"). The Offer and withdrawal rights expired as scheduled at 12:00 midnight, New York City Time, on January 19, 2018. AAA is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |